BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16029926)

  • 1. DNA hypermethylation in breast cancer and its association with clinicopathological features.
    Li S; Rong M; Iacopetta B
    Cancer Lett; 2006 Jun; 237(2):272-80. PubMed ID: 16029926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors.
    Parrella P; Poeta ML; Gallo AP; Prencipe M; Scintu M; Apicella A; Rossiello R; Liguoro G; Seripa D; Gravina C; Rabitti C; Rinaldi M; Nicol T; Tommasi S; Paradiso A; Schittulli F; Altomare V; Fazio VM
    Clin Cancer Res; 2004 Aug; 10(16):5349-54. PubMed ID: 15328171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers.
    Archey WB; McEachern KA; Robson M; Offit K; Vaziri SA; Casey G; Borg A; Arrick BA
    Oncogene; 2002 Oct; 21(46):7034-41. PubMed ID: 12370825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
    Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
    Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation in histologically distinct classes of breast cancer.
    Bae YK; Brown A; Garrett E; Bornman D; Fackler MJ; Sukumar S; Herman JG; Gabrielson E
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a role of the Simian Virus 40 in human breast carcinomas.
    Hachana M; Trimeche M; Ziadi S; Amara K; Korbi S
    Breast Cancer Res Treat; 2009 Jan; 113(1):43-58. PubMed ID: 18205041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
    Murao K; Kubo Y; Ohtani N; Hara E; Arase S
    Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
    Hu XC; Wong IH; Chow LW
    Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
    Bean GR; Ibarra Drendall C; Goldenberg VK; Baker JC; Troch MM; Paisie C; Wilke LG; Yee L; Marcom PK; Kimler BF; Fabian CJ; Zalles CM; Broadwater G; Scott V; Seewaldt VL
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):50-6. PubMed ID: 17220331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
    Lewis CM; Cler LR; Bu DW; Zöchbauer-Müller S; Milchgrub S; Naftalis EZ; Leitch AM; Minna JD; Euhus DM
    Clin Cancer Res; 2005 Jan; 11(1):166-72. PubMed ID: 15671542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in human breast cancer.
    Li SY; Rong M; Iacopetta B
    Oncol Rep; 2006 Jan; 15(1):221-5. PubMed ID: 16328059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls.
    Bosviel R; Garcia S; Lavediaux G; Michard E; Dravers M; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
    Cancer Epidemiol; 2012 Jun; 36(3):e177-82. PubMed ID: 22402307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.